Malaria

ch.5 pp255-69

Dr. Afnan Younis, MPH, SBCM

Assistant Professor, Community Medicine

ayounis@ksu.edu.sa

Afnan.younis@gmail.com

Objectives:


- 1. Understand the epidemiology and global burden of malaria
- 2. Define modes of transmission, clinical features, risk factors, community diagnosis and treatment of malaria
- 3. Enlist factors responsible for antimalarial drug resistance
- 4. Understand the role and measures taken by WHO to combat the burden of Malaria globally
- 5. Understand the epidemiology and risk factors related to Malaria in KSA


- Malaria is a life-threatening disease caused by
 Plasmodium parasites that are transmitted to people through the bites of infected mosquitoes.
- Malaria is responsible for approximately 1-3 million deaths per year

Epidemiology

- In 2016, there were 216 million cases and 445,000 deaths caused by malaria worldwide.
- . Between 2000 and 2015, malaria incidence fell by 37% globally.
- During the same period, malaria **mortality** rates decreased worldwide by 60% among all age groups, and by 65% among children under 5.
- In 2014, 13 countries reported zero cases of the disease and 6 countries reported fewer than 10 cases.

Classification of countries by stage of malaria elimination, as of December 2014





An approximation of the parts of the world where malaria transmission occurs.


Malaria in Saudi Arabia

- Areas at the **southern region** are at risk of malaria transmission, specifically Asir and Jizan. The Dominant Malaria Species in Saudi Arabia is **P. Falciparum**.
- •Saudi Arabia achieved a decrease in malaria cases and case incidence rates of ≥75%.

Malaria in Saudi Arabia

- Malaria outbreak in 1998.
- •Since then, only a few cases were reported
- •In 2012, only 82 cases of malaria were reported..
- •The proportion of imported malaria has increased from 23% to 99% of total detected cases.

Indigenous cases of malaria Saudi Arabia 2014:



Year

Imported malaria in Saudi Arabia 1999-2010:





Fig. 1. Indigenous and imported malaria in Saudi Arabia, 1999-2010 (Cotter et al., 2013).

Imported malaria: via asymptomatic travelers from malaria endemic areas, sustains a threat for possible resurgence of local transmission: Workers, immigrants, pilgrims.

Analytical Epidemiology Triad:

HOST



AGENT

ENVIRONMENT

Plasmodium Parasites

• Five species cause malaria in humans:


Plasmodium falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi

• P. falciparum and P. vivax pose the greatest threat.

Plasmodium Parasites

- Transmitted through the bites of infected female Anopheles mosquitoes (vector).
- Other modes of transmission:
- From mother to unborn child
- Blood transfusion


Plasmodium Parasites transmission and lifecycle:



Clinical features



Paroxysmal fever



Cold stage: lassitude, headache, nausea, chills. (¼ -1 h) skin cold then hot

Hot stage: skin hot and dry (2 -6 h)

Sweating stage: fever subsides, sweating (2 -4 h)

Symptoms

Early symptoms

Fever

Headache

Chills

If not treated early might progress to

Severe illness

Severe anemia

Respiratory distress

Cerebral malaria

Multiorgan failure

Risk factors

No or little immunity against the disease in areas with high transmission


- Young children, who have not yet developed partial immunity to malaria
- Pregnant women, whose immunity is decreased by pregnancy.
- Travelers or migrants coming from areas with little or no malaria transmission, who lack immunity.
- People with low immunity such as HIV patients
- Poverty
- Environmental: rain seasons

Immunity against malaria (protection)

- * Genetic Factors: Biologic characteristics present from birth can protect against certain types of malaria: (having the sickle cell trait)
- * Acquired Immunity: newborns in endemic areas will be protected during the first few months by maternal antibodies.
- * Repeated attacks of malaria

Diagnosis

- Microscopy: thin film, thick film
- Serology: two weeks after infection, past infection in epidemiological studies.
- Rapid diagnostic test (RDT):



Community diagnosis

- Pre-eradication: spleen rate, parasite rate,.....
- Eradication: microscopic diagnosis
 - Parasite incidence
 - Blood examination rate
- Vector indices
 - Human blood index
 - Sporozite rate
 - Mosquito density
 - Man biting rate
 - Inoculation rate

Treatment

Choice of treatment line depends on:

- Type of plasmodium species and stages of malaria parasites.
- Clinical status of patient: Uncomplicated or Severe, or pregnancy.
- Drug sensitivity of the infected parasite (area)
- Previous exposure to anti-malarial drugs.

Artemisinin combination therapy (ACT): (3days)

 Monotherapy is not recommended for malaria treatment to prevent drug resistance

For uncomplicated malaria:

First line: (ARTESUNATE + SP); alternative (ARTESUNATE + MEFLOQUINE)

Second Line: (ARTEMETHER + LUMEFANTRINE)

Third Line: (oral QUININE + DOXYCYCLINE)

A single dose of Primaquine is added to the first day as a gametocidal medication.

- Primaquine is contraindicated in:
 - G6PG deficiency,
 - pregnancy,
 - children < 6m,
 - lactating mothers for babies <6m or
 - hypersensitivity

Treatment failure

- Failure to resolve or recurrence of fever or parasitemia:
- Early (1-3 days of treatment)
- Late: (4days 6 weeks after treatment)
- Causes:
- Poor adherence to treatment
- Low or incomplete dose
- Abnormal individual pharmaokinetics
- Drug resistance

Antimalarial drug resistance

• The ability of the parasite to survive and/or multiply despite the administration and absorption of medication.

Reason:

- Exposure of the parasite to insufficient amount of the drug.
 - Low dose prescribed
 - Lesser amount dispensed
 - Incomplete treatment
 - Vomiting
 - Low absorption

WHO efforts in malaria control

- Global Technical Strategy for Malaria 2016–2030
- Ensure universal access to malaria prevention, diagnosis and treatment
- 2. Accelerate efforts towards elimination and attainment of malariafree status
- 3. Transform malaria surveillance into a core intervention

Control:

The main way to reduce malaria transmission at a community is vector control

- Decrease human-mosquito contact
- Destruction of adult mosquitoes
- Destruction of larvae
- Environmental control
- Chemoprophylaxis
- Vaccination



Decrease human-mosquito contact

- Insecticide-treated mosquito nets (ITNs)
- For all at-risk persons
- Provision of free LLINs
- Everyone sleeps under a LLIN every night.



Destruction of adult mosquitoes

- Indoor spraying with residual insecticides
- At least 80% of houses in targeted areas are sprayed
- Protection depends on type of insecticide.





Destruction of mosquito larvae

• Larviciding of water surfaces, intermittent irrigation, biological control



Source reduction

• Environmental sanitation, water management, drainage



Social participation

• Health education , community participation

Chemoprophylaxis

- To travelers
- Pregnant women
- Infants in endemic areas
- Seasonal chemoprevention



Vaccination

Still under trial



Risk factors in Saudi Arabia

- Heavy rainfall season
- Army personnel and employees working at the Southern borders
- Travelers to countries with active malaria transmission
- Pilgrimage from regions with active malaria transmission

Prevention and control of malaria in KSA

The current elimination strategy in Saudi Arabia focuses mainly on:

- 1. Targeting **high risk areas** for sustained preventative measures such as (Long lasting insecticide treated nets, Indoor residual spraying)
- 2. Management of infection through rapid confirmed diagnosis and treatment.
- 3. Individual case follow up and reactive **surveillance** with appropriate treatment and vector control.
- 4. Active case detection at borders with screening and treatment.

Malaria and Hajj season

Measures applied before inlet of Pilgrims:

- Spray health care facilities pilgrims camps with residual insecticides.
- Surveillance at Hajj Entry ports (suspected cases/ necessary measures).

Measures applied during Hajj season:

- Epidemiology investigation malaria cases (proper diagnosis/treatment).
- Secure malaria drugs and treatment policy for all health care facilities.

References

- Park K. Park's Txtbook of Preventive and Social Medicine. 23rd edition. India: Bhanot, 2015
- WHO. 2018. Malaria surveillance, monitoring & evaluation: a reference manual.
- WHO. 2016. Global Technical Strategy for Malaria 2016–2030
- WHO. 2017. A Framework for Malaria Elimination
- MOH. 2005. National Malaria Policy.
- http://www.who.int/mediacentre/factsheets/fs094/en/.
- http://www.cdc.gov/malaria/about/biology/human_factors.html